Massive 50,000-Patient study tracks new kidney drug in real world
NCT ID NCT06278207
Summary
This study is collecting information about how a recently approved kidney medication called finerenone is actually used by patients in everyday medical care. Researchers will analyze existing health records from 50,000 people in the US and Asia who have both chronic kidney disease and type 2 diabetes and have started taking finerenone. The goal is to understand who gets prescribed this drug, how they take it, and what health outcomes they experience in real-world settings.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bayer
RECRUITINGBerlin, 13353, Germany
-
Many Locations
COMPLETEDMultiple Locations, New Jersey, 07981, United States
-
Many Locations
COMPLETEDMultiple Locations, Japan
-
Many Locations
COMPLETEDMultiple Locations, Taiwan
Conditions
Explore the condition pages connected to this study.